Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PANK1 | Q8TE04 | 1/20 | 0.45 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657680 | 0.90 | TAAR1 (0.50) | TP53HPGDTRPV1 | |
| SCHEMBL1787971 | 0.86 | KMT2A (0.49) | TP53ALDH1A1RAB9AHPGDTRPV1 | |
| SCHEMBL1658203 | 0.85 | LMNA (0.62) | POLBLMNATP53ALDH1A1HPGD | |
| SCHEMBL1786020 | 0.85 | GAA (0.60) | LMNAGAASRCALDH1A1HPGD | |
| SCHEMBL1658871 | 0.81 | MEN1 (0.54) | POLBFOLH1ALDH1A1RAB9A | |
| SCHEMBL1659422 | 0.79 | MAPT (0.64) | LMNAALDH1A1MAPK1 | |
| SCHEMBL1188758 | 0.79 | LMNA (0.44) | LMNASRCALDH1A1MAPK1RAB9A | |
| SCHEMBL1785229 | 0.79 | ALDH1A1 (0.52) | LMNAGAAFOLH1ALDH1A1MAPK1 | |
| SCHEMBL1658851 | 0.78 | ALDH1A1 (0.60) | POLBLMNAALDH1A1RAB9AHPGD | |
| SCHEMBL1659441 | 0.77 | HPGD (0.59) | POLBLMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | claimed |
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9090576-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8716527-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | PTC THERAPEUTICS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2262508-A2 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111576-A2 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | POLB 267/4885LMNA 1369/4885GAA 187/4885 |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | POLB 267/4885LMNA 1369/4885GAA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.